RxDoctor Payments Data

Richard Marques

Internal Medicine · Boca Raton, FLNPI 1811957749

Payments from drug & device makers

$41,992in general payments, 2019–2025

Across 1,783 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • AbbVie$6K
  • Novo Nordisk$4K
  • Lilly USA, LLC$3K
  • Amgen$3K
  • GSK$3K
  • plus $17K from 54 others

What the payments were for

  • Food & beverage$41,979100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca227$6,435
AbbVie(2 entities)302$5,827
Novo Nordisk168$3,505
Lilly USA, LLC160$3,487
Amgen(2 entities)154$3,015
GSK97$2,958
Boehringer Ingelheim78$2,012
Pfizer74$1,966
Biohaven Pharmaceuticals, Inc.39$1,447
Gilead40$1,162
Sanofi-aventis U.S. LLC45$995
Novartis38$804
Amarin Pharma, Inc.28$741
Johnson & Johnson22$718
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC33$712
Bayer19$519
Idorsia Pharmaceuticals US Inc14$411
Alkermes, Inc.13$407
Exact Sciences21$398
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)18$392
Axsome Therapeutics, Inc.11$313
Biohaven Pharmaceutical Holding Company Ltd.11$287
Phathom Pharmaceuticals, Inc.3$258
Almatica Pharma LLC16$249
Takeda Pharmaceuticals U.S.A., Inc.12$247
Viiv Healthcare Company10$213
Kowa Pharmaceuticals America, Inc.12$199
Merck11$174
E.r. Squibb & Sons, L.L.C.9$163
Eisai Inc.10$157
Lundbeck LLC6$123
Astellas Pharma US Inc5$115
Melinta Therapeutics, LLC7$114
Intuitive Surgical1$100
Vanda Pharmaceuticals Inc.4$93
Supernus Pharmaceuticals, Inc.5$92
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$92
Actelion Pharmaceuticals US, Inc.4$85
Teva Pharmaceuticals USA, Inc.4$70
Otsuka America Pharmaceutical, Inc.3$63
Antares Pharma, Inc.4$62
Phadia US Inc.2$49
Ardelyx, Inc.2$47
Aimmune Therapeutics, Inc.2$45
Dexcom, Inc.2$44
Genentech USA, Inc.2$44
Kvk-tech, Inc.3$41
Nabriva Therapeutics, PLC2$34
Lucid Diagnostics Inc.2$33
Paratek Pharmaceuticals, Inc.2$33
Coherus Oncology, Inc.1$28
Upsher-smith Laboratories LLC2$28
Verona Pharma, Inc.1$28
Jazz Pharmaceuticals Inc.2$28
Abbott2$27
Nalpropion Pharmaceuticals LLC2$26
Heartflow, Inc.1$25
Inspire Medical Systems, Inc.1$23
Mylan Institutional Inc.1$23
Dermira, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,992 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$170,580
Medicare patients
255
Services billed
1,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$121,702
EliquisApixaban67$91,412
MounjaroTirzepatide63$87,754
Breztri AerosphereBudesonide/Glycopyr/Formoterol75$78,436
JardianceEmpagliflozin42$54,753
LinzessLinaclotide50$47,726
XareltoRivaroxaban43$44,724
Repatha SureclickEvolocumab44$43,310
Soliqua 100-33Insulin Glargine/Lixisenatide22$39,320
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$35,450
FarxigaDapagliflozin Propanediol25$33,178
EntrestoSacubitril/Valsartan17$17,346
VascepaIcosapent Ethyl20$13,650
Tresiba Flextouch U-100Insulin Degludec12$9,451
PremarinEstrogens, Conjugated22$8,386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Brilinta$6,435$124,679128 claims
Novo NordiskOzempic$3,505$121,702100 claims
PfizerEliquis, Premarin$1,966$99,79889 claims
Lilly USA, LLCMounjaro$3,487$87,75463 claims
Boehringer IngelheimJardiance$2,012$54,75342 claims
AbbVieLinzess$5,827$47,72650 claims
Johnson & JohnsonXarelto$718$44,72443 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$995$39,32022 claims
GSKTrelegy Ellipta$2,958$35,45038 claims
NovartisEntresto$804$17,34617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →